{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:58:21Z","timestamp":1777521501841,"version":"3.51.4"},"reference-count":34,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Exper Ophthalmology"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Importance<\/jats:title><jats:p>To examine the effect of switching from intravitreal bevacizumab or ranibizumab to aflibercept in eyes with persistent macular oedema due to retinal vein occlusion (RVO).<\/jats:p><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>We report the results of a prospective interventional study on the effect of aflibercept 2\u2009mg in eyes with persistent macular oedema after long\u2010term treatment with bevacizumab or ranibizumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Non\u2010randomized, prospective clinical trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Eighteen eyes of eighteen patients were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Eyes with persistent macular oedema despite a minimum of four previous intravitreal bevacizumab\/ranibizumab injections were recruited into this 48\u2010week trial. Three loading doses of intravitreal aflibercept were administered every 4\u2010weeks, thereafter every 8\u2010weeks until week 48.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcome Measures<\/jats:title><jats:p>Mean change from baseline in best corrected visual acuity (BCVA) as measured by early treatment diabetic retinopathy score (ETDRS) and central macular thickness (CMT) as measured by spectral domain optical coherence tomography (SD\u2010OCT) at 48\u2009weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients had received a mean of 40.0\u2009\u00b1\u200917.8 bevacizumab\/ranibizumab intravitreal injections prior to switching to aflibercept. The mean number of previous injections administered in the 12\u2010months preceding entry into the study was 10.2\u2009\u00b1\u20092.4. Mean vision change at week 48 was +21.1\u2009\u00b1\u20095.1 ETDRS letters in the BRVO group and +18.8\u2009\u00b1\u20095.9 letters at in the CRVO group (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.001 for both groups). Mean decrease in CMT was 87.6\u2009\u00b1\u200948.8 \u03bcm and 191.0\u2009\u00b1\u2009128.3 \u03bcm, in the BRVO and CRVO groups, respectively (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.001). Using linear regression analyses, a higher number of previous intravitreal ranibizumab\/bevacizumab injections and thicker pre\u2010switch CMT were correlated with greater visual gains.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion and relevance<\/jats:title><jats:p>Switching to aflibercept from bevacizumab or ranibizumab in eyes with persistent macular oedema due to RVO can lead to functional and anatomical improvement. This effect was more obvious in eyes with a greater CMT prior to the switch.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ceo.13636","type":"journal-article","created":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T16:57:38Z","timestamp":1568048258000},"page":"53-60","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long\u2010term treatment with bevacizumab or ranibizumab"],"prefix":"10.1111","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5096-3786","authenticated-orcid":false,"given":"Kimberly","family":"Spooner","sequence":"first","affiliation":[{"name":"Sydney Retina  Sydney New South Wales Australia"},{"name":"Sydney Institute of Vision Science  Sydney New South Wales Australia"},{"name":"Save Sight Institute, The University of Sydney  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Fraser\u2010Bell","sequence":"additional","affiliation":[{"name":"Sydney Retina  Sydney New South Wales Australia"},{"name":"Save Sight Institute, The University of Sydney  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Hong","sequence":"additional","affiliation":[{"name":"Sydney Retina  Sydney New South Wales Australia"},{"name":"Sydney Institute of Vision Science  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Chang","sequence":"additional","affiliation":[{"name":"Sydney Retina  Sydney New South Wales Australia"},{"name":"Sydney Institute of Vision Science  Sydney New South Wales Australia"},{"name":"Save Sight Institute, The University of Sydney  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,10,10]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.04.019"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.08.012"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.09.026"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.4568"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0365-6691(12)70051-5"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20170601-04"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2017.6843"},{"key":"e_1_2_7_9_1","volume-title":"FDA Approves Lucentis (Ranibizumab Injection) for the Treatment of Macular Edema Following Retinal Vein Occlusion","author":"Genentech","year":"2010"},{"key":"e_1_2_7_10_1","volume-title":"Regeneron Announces FDA Approval of Eylea\u00ae (Aflibercept) Injection for Macular Edema Following Central Retinal Vein Occlusion","author":"Regeneron","year":"2012"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S125676"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/4095852"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-017-3624-y"},{"issue":"1","key":"e_1_2_7_14_1","first-page":"207","article-title":"Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab","volume":"38","author":"Konidaris V","year":"2017","journal-title":"Int Ophthalmol"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001304"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-22725"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-9950"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2016.02.001"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1545783"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2015.175"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000439223"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-016-0045-8"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2017.10.008"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-20474"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-008-0106-7"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000477856"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.15-17338"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S128651"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001493"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1507735"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.13-248021"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2017-311614"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1159\/000327391"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4816527"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep43509"}],"container-title":["Clinical &amp; Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ceo.13636","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ceo.13636","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ceo.13636","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T19:52:46Z","timestamp":1694116366000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ceo.13636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,10]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1111\/ceo.13636"],"URL":"https:\/\/doi.org\/10.1111\/ceo.13636","archive":["Portico"],"relation":{},"ISSN":["1442-6404","1442-9071"],"issn-type":[{"value":"1442-6404","type":"print"},{"value":"1442-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,10]]},"assertion":[{"value":"2019-07-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}